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The gastric antral vascular ectasia (GAVE) is a well recognizable endoscopic entity charac-
terized by the presence of multiple linear angioectatic vessels predominantly located in the
antrum, with a typical appearance of “watermelon stomach”. This condition typically affects
elderly females presenting as iron-deﬁciency anaemia due to chronic gastric bleeding. Stan-
dard  treatment is endoscopic ablation of the gastric mucosa. For non-responders, radical
surgery is considered a curative treatment but with considerable morbidity and mortality.
Radiation therapy is a well-known alternative for many benign diseases, including anoma-adiotherapy
atermelon
ransfusion requirements
ocal control
lous  vascular hyperproliferative diseases, although its role has not been deﬁned for GAVE.
The  present case illustrates the efﬁcacy and tolerance of radiotherapy in the treatment of
symptomatic gastric watermelon.
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trectomy specimen from an old woman. It was described as
“erosive atrophic gastritis with remarkable venous capillaries
6. Background
astric antral vascular ectasia (GAVE) is a rare but well
escribed cause of recurrent upper gastrointestinal bleed-
ng in the elderly manifested clinically as iron-deﬁciency
naemia. Its prevalence varies between less than 0.3% of cases
n large endoscopic series and up to 4% in selected series with
atients being studied for upper gastrointestinal bleeding of
ncertain origin.1 GAVE prevalence is higher among elderly
emales, with a 5:1 female preponderance. Patients are usually
ransfusion dependent with average requirements as high as
0–100 units of blood per year in severe cases.2–4
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GAVE’s etiology is unclear. Immunological disturbances
such as systemic lupus, scleroderma, systemic sclerosis,
pernicious anemia or primary biliary cirrhosis have been
associated to this disease. Also, GAVE has been related to
non-immunitary disorders, such as chronic renal dysfunction,
hepatic cirrhosis, ischemic cardiomyopathy, diabetes melli-
tus, familiar Mediterranean fever or after haematopoietic cell
transplantation.2,5
GAVE was initially reported in 1953 by Ryder et al. in a gas-ry Hospital Ramón y Cajal, Cta/ Colmenar Viejo Km. 9.100, 28034
ectasia”. In 1984, Jabbari et al. coined the expression “water-
melon stomach”, describing a typical endoscopic appearance
ed by Elsevier Urban & Partner Sp. z.o.o. All rights reserved.
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with red stripes and/or erythematous areas corresponding to
dilated blood vessels.7
GAVE’s treatment aims to minimize, or even eliminate,
blood transfusion requirements. Therapeutic approaches
have included endoscopic ablation techniques, pharmacolog-
ical treatments and surgery, but with variable results.
Radiotherapy has been employed for treatment of different
vascular disorders, not necessarily of malignant etiology. In
the past, low dose radiotherapy was used for treatment of pep-
tic ulcer disease and associated gastric or duodenal bleeding
with good results.8
2. Aim
We  present an own clinical case of a woman treated with
radiotherapy for persistent GAVE after other therapies, which
highlights the effectiveness and well tolerance of radiation
therapy, supporting its consideration after failure of other
standard treatments.
3.  Case  report
A 77 year-old woman, with a previous medical history of
type II diabetes mellitus and hypertension, had been diag-
nosed 3 years before her attendance of GAVE. She was
consulted because of iron-deﬁciency anaemia due to chronic
gastric bleeding leading to weekly blood transfusions. Oral
gastroscopy evidenced the presence of an antral vascular ecta-
sia with typical red stripes found in watermelon stomach.
The patient began to be treated with oral iron-supplements
and estrogens. By the time of the diagnosis, no signs or
symptoms of hepatopathy were manifested. For the next two
years, the patient was treated with several argon-plasma
coagulations (APC) of GAVE lesions localized in the gastric
antrum. One year after the initial diagnosis she developed
signs of chronic hepatopathy and portal hypertension with-
out hydropic decompensation, persisting the GAVE lesions
in the antrum. Despite sequential endoluminal APC, the
patient continued with refractory anaemia, requiring 1–2
blood transfusions per week. An oral endoscopy showed grade
II oesophageal varicose veins without evidence of active bleed-
ing, as well as multiple aberrant vascular formations located
Fig. 1 – (A and B) Endoscopic view from gastric mucosae, showin
disposition and antral predominance typical of GAVE.iotherapy 1 7 ( 2 0 1 2 ) 233–236
mainly in the antrum and occasionally in the fundus and
stomach body, with classic aspect of GAVE (Fig. 1A and B). Due
to the persistence of the GAVE lesions despite the treatments
administered, other therapeutic options were considered. The
patient refused surgical treatment and was remitted to our
department. At her attendances, laboratory ﬁndings showed
haemoglobin of 8.2 g/dl, hematocrit of 30% and normal hep-
atic function, platelet count, prothrombin time and INR. A
radiation treatment was proposed and the patient signed
an informed consent. After patient immobilization using an
individualized alpha-cradle to ensure daily repositioning, we
performed a CT-scan acquisition of the thorax and abdomen at
5-mm-thin intervals. The clinical target volume (CTV), involv-
ing all GAVE lesions along with the surrounding organs at
risk (spine, lungs, heart, kidneys, liver and spleen) were con-
toured on CT slices. A security margin was added to the CTV to
compensate the physiological organ movements and potential
inaccuracies in the daily positioning of the patient, establish-
ing the planning target volume (PTV). A total dose of 20 Gy
for the PTV, with conventional 2 Gy-daily fractionation, ﬁve
days a week, was prescribed. The treatment was carried out
by a linear accelerator using multiple conformed ﬁelds with 6
MV photons. Oral antiemetic prophylaxis with a 5-HT3 recep-
tor antagonist was given to the patient to avoid radio-induced
emesis.
At discharge, the patient was in a stable condition. A
repeated oral endoscopy three months after radiotherapy
ﬁnalization only showed isolated petequial dotted in the
antrum, fundus and body of the stomach, suggestive of
chronic pangastritis. No endoluminal therapy was necessary
at that time (Fig. 2A and B). No more  blood transfusions were
needed.
4. Discussion
Although GAVE is a relatively infrequent disorder, it has to
be considered in the context of a chronic or acute gastroin-
testinal bleeding in older patients. The most common clinical
presentation is a chronic occult gastrointestinal bleeding that
leads to the establishment of symptomatic anaemia, although
it has also been described as an acute massive gastroin-
testinal bleeding. Frequently, the patient does not respond
to iron replacement therapy and becomes highly dependent
g lesions with vascular aspect, congestive, with lineal
reports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 233–236 235
Fig. 2 – (A–C) Endoscopic view of antral mucosa 3-months after radiotherapy showing images with petequial aspect,
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n blood transfusions.2–4 Several immunological as well as
on-immunological diseases have been associated to GAVE
evelopment. Nevertheless, the most frequently comorbidity
ssociated with GAVE is hepatic cirrhosis that can be found in
0–66% of the patients with a diagnosis of GAVE. In those cases,
ifferential diagnosis between portal hypertension gastropa-
hy (PHG), typically present in hepatic cirrhosis, and GAVE
ight be quite difﬁcult. However, GAVE affects mainly the
astric antrum while PHG is more  prevailing in the body and
undus. In this case we present, the patient has chronic hep-
topathy signs but she has not required any speciﬁc treatment
o far.5
The pathogeny for GAVE has not been well established. Dif-
erent hypotheses have been proposed: (1) mechanical stress
aused by elevated gastric peristalsis; (2) fusiform cells pro-
iferation, due to hypergastrimenia, frequently observed in
atients with GAVE, causing high venous pressure, and (3)
ocal neuroendocrine cells proliferation, achieving high levels
f vasoactive substances, such as VIP and serotonin, directly
mplicated in vascular dilatation.5 The endoscopic aspect is
iagnostic. The presence of the characteristically red stripes
ith a watermelon appearance is considered pathognomonic
or this entity. Gastric biopsies offer a valuable tool with high
ensitivity for GAVE, but the bleeding risk is far from negligible.
ngiography shows antral hypervascularisation and ecoen-
oscopy allows to observe vascular ectasia in mucosae and
ubmucosae, but although usefully, they are not considered
ecessary for the diagnosis of GAVE.2,4
The objective of the treatment is to eliminate or min-
mise blood transfusion needs. The therapeutic options for
AVE rely on three categories: surgical, endoluminal and phar-
acological. Endoscopic treatments are considered the ﬁrst
ption. Nd:YAG laser has been widely used but it rarely pro-
ides a complete cure. Most patients need several sessions and
etween 14% and 50% continue with the need of transfusion
uring follow-up.2,5,9 Endoscopic argon-plasma coagulation
APC) also offers similar clinical results to those achieved with
d:YAG laser with a limited penetration, which reduces ulcer-
tion and perforation.10 Other endoscopic modalities used
ccasionally have been contact termocoagulation with ther-
al  catheter, bipolar electrocoagulation and sclerotherapy
2,5ith alcohol or polidocanol injections.
Surgical antrectomy is the most curative option for GAVE,
s evidenced by the fact that none of the patients suffered
naemia or gastrointestinal bleeding after surgery.6,8 However,ritis.
it is still the last option because of its high morbidity–mortality
rates (5–10%), and its use must be limited to patients refractory
to conservative treatments.1,2,5
Finally, pharmacological treatment for GAVE employing
beta blockers, corticosteroids, hormonal treatments with
estrogens and progesterone, octreotide, tranexamic acid,
thalidomide or ciproheptadine have been tested by several
authors in small series with no conclusive results.2,5
Radiotherapy effectiveness for benign diseases is sup-
ported by a broad evidence of scientiﬁc publications.11,12
Moderate dose radiotherapy has proved its value in the treat-
ment of many  disorders characterized by anomalous vascular
proliferation, including angiomas, arteriovenous malforma-
tions, Rendu–Osler–Weber syndrome or age-related macular
degeneration. The beneﬁt of radiotherapy in these pathologies
is based on its apparent ability to prevent the prolifer-
ation of neovascular endothelium, stimulating apoptosis
phenomenon in the endothelial cells, and its capacity to
induce the regression of this neovascularisation as well as
inhibiting the new vessels array.13,14 Risk of development of
radiation-induced tumours has raised concerns about radio-
therapy for non-malignant diseases. However, according to
the most recent reviews, this risk appears almost negligible
in elderly patients, as occurs in patients with GAVE.15
5.  Results
In our patient, not only the ﬁnal dose but also the fractiona-
tion scheme was chosen with the objective of limiting the risk
of acute and late radiation toxicity. Although, the ﬁnal dose
was empirically ﬁxed at 20 Gy, there is enough experience in
other benign diseases characterized by vascular hyperprolifer-
ation with radiation doses ranging between 20 and 30 Gy.11–14
Radiation tolerance was excellent, allowing outpatient treat-
ment without hospitalization or blood transfusions during the
procedure. Although follow-up is still not too long, 3 months
after radiotherapy ending, the patient is free of new blood-
transfusion requirements.6.  Conclusion
In conclusion, despite few data in the literature, radiotherapy
can be an effective and well tolerated treatment for GAVE, and
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could be considered as an alternative when the conventional
treatments have failed.
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